公开(公告)号：US20200230234A1

公开(公告)日：2020-07-23

申请号：US15760424

申请日：2016-09-21

Applicant: MOLOGEN AG

Inventor： Matthias SCHROFF ,  Manuel SCHMIDT ,  Kerstin KAPP ,  Alfredo ZURLO ,  Ole SCHMELTZ SOGAARD ,  Martin TOLSTRUP ,  Rasmus OFFERSEN

IPC: A61K39/39 ,  A61K31/711 ,  C12N15/117 ,  C12N15/113

Abstract: The invention relates to a non-coding sequence of deoxyribonucleic acids comprising at least one sequence motif N1N2CGN3N4, wherein N is a nucleotide comprising A, C, T, or G, and C is deoxycytidine, G is deoxyguanosine, A is deoxyadenosine and T is deoxy-thymidine for the treatment of viral infections. In particular, the non-coding sequence of deoxyribonucleic acids is used in combination with antiretroviral therapy and/or histone de-acetylase inhibitors.

公开(公告)号：US20160115479A1

公开(公告)日：2016-04-28

申请号：US14891869

申请日：2014-05-15

Applicant: MOLOGEN AG

Inventor： Matthias Schroff ,  Manuel Schmidt ,  Kerstin Kapp ,  Burghardt Wittig

IPC: C12N15/117 ,  A61K39/39 ,  G01N33/574

CPC classification number: C12N15/117 ,  A61K39/39 ,  C12N2310/17 ,  C12N2310/531 ,  C12N2320/30 ,  G01N33/5091 ,  G01N33/574 ,  G01N2333/70503 ,  G01N2333/7051 ,  G01N2333/70596 ,  G01N2469/00 ,  G01N2800/52

Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

Abstract translation: 本发明一般涉及患有癌症的患者是否对特定疗法作出反应。 更具体地，本发明涉及用于鉴定治疗TLR-9激动剂的应答者的方法和手段。

公开(公告)号：US20210010003A1

公开(公告)日：2021-01-14

申请号：US16793334

申请日：2020-02-18

Applicant: Mologen AG

Inventor： Matthias Schroff ,  Manuel Schmidt ,  Kerstin Kapp ,  Alfredo Zurlo

IPC: C12N15/117 ,  C12N15/11 ,  C07K16/30 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/7088

Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAG3, CD137(4-1BB) and a non-coding immunomodulating DNA.

公开(公告)号：US20190316134A1

公开(公告)日：2019-10-17

申请号：US16450324

申请日：2019-06-26

Applicant: Mologen AG

Inventor： Matthias SCHROFF ,  Manuel SCHMIDT ,  Kerstin KAPP ,  Alfredo ZURLO

IPC: C12N15/117 ,  C07K16/30 ,  A61K39/395 ,  C07K16/28 ,  A61K31/7088 ,  A61P35/00 ,  C12N15/11

Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.

公开(公告)号：US10006032B2

公开(公告)日：2018-06-26

申请号：US14891869

申请日：2014-05-15

Applicant: Mologen AG

Inventor： Matthias Schroff ,  Manuel Schmidt ,  Kerstin Kapp ,  Burghardt Wittig

IPC: C12N15/117 ,  G01N33/50 ,  G01N33/574 ,  A61K39/39

Abstract: The present invention relates generally to the identification of patients suffering from cancer whether they will respond to specific therapies. More particularly the invention relates to a method and means for identifying responder to a therapy TLR-9 agonists.

公开(公告)号：US20150328308A1

公开(公告)日：2015-11-19

申请号：US14739570

申请日：2015-06-15

Applicant: MOLOGEN AG

Inventor： Sonia Moreno-Lopez ,  Marcos Timon-Jimenez

IPC: A61K39/385 ,  A61K39/008 ,  A61K39/29

CPC classification number: A61K39/385 ,  A61K39/008 ,  A61K39/12 ,  A61K39/29 ,  A61K2039/53 ,  A61K2039/57 ,  A61K2039/6031 ,  C12N2730/10134 ,  Y02A50/41 ,  Y02A50/412

Abstract: A method of eliciting a cytotoxic immune response as a result of injecting antigen encoding expression constructs. Minimalistic expression constructs are used that comprise a promoter, a coding sequence and a terminator, and hairpin-shaped oligonucleotides on their ends, to the loop of which cationic peptides are covalently attached. These peptide-coupled expression constructs lead to a cell mediated response type after intradermal injection. The use of a DNA expression construct operable in eukaryotic cells for making a vaccine for intradermal injection to elicit a type 1 cell mediated immune mediated immune response is described.

Abstract translation: 作为注射抗原编码表达构建体的结果引起细胞毒性免疫应答的方法。 使用包含启动子，编码序列和终止子以及其末端的发夹形寡核苷酸到共价连接阳离子肽的环的简约表达构建体。 这些肽偶联的表达构建体在皮内注射后导致细胞介导的应答型。 描述了在真核细胞中可用于制备用于真皮内注射的疫苗以引发1型细胞介导的免疫介导的免疫应答的DNA表达构建体的用途。

公开(公告)号：US20130287814A1

公开(公告)日：2013-10-31

申请号：US13996829

申请日：2011-12-23

Applicant: MOLOGEN AG

Inventor： Matthias Schroff ,  Christiane Kleuss ,  Kerstin Kapp

IPC: C12N15/85

CPC classification number: C12N15/85 ,  A61K48/00 ,  C12N2800/24

Abstract: The invention relates to a minimalistic gene expression construct, its transfer into cells and its use for gene expression for molecular-medical applications. According to the disclosure, a DNA construct for gene expression is provided, wherein the construct is a linear and open-chained DNA double strand comprising a promoter sequence, a coding sequence and a termination signal, wherein the construct comprises at least one L-DNA nucleotide.

Abstract translation: 本发明涉及简约基因表达构建体，其转移到细胞中及其用于分子医学应用的基因表达的用途。 根据本公开，提供了用于基因表达的DNA构建体，其中所述构建体是包含启动子序列，编码序列和终止信号的线性和开链DNA双链，其中所述构建体包含至少一个L-DNA 核苷酸。

公开(公告)号：US20210079403A1

公开(公告)日：2021-03-18

申请号：US16642270

申请日：2018-08-31

Applicant: Mologen AG

Inventor： Manuel SCHMIDT ,  Kerstin KAPP

IPC: C12N15/113 ,  A61K47/02 ,  A61P35/00 ,  A61K9/08

Abstract: A TLR-9 agonist for use in the treatment of a tumor disease, in particular of colon cancer, and for the modulation of the tumor microenvironment.

公开(公告)号：US10604760B2

公开(公告)日：2020-03-31

申请号：US16450324

申请日：2019-06-26

Applicant: Mologen AG

Inventor： Matthias Schroff ,  Manuel Schmidt ,  Kerstin Kapp ,  Alfredo Zurlo

IPC: C12N15/117 ,  C12N15/11 ,  C07K16/30 ,  C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/7088 ,  A61K39/00

Abstract: The invention relates to a combination and its use for the treatment of diseases. The instant disclosure provides a combination of a so-called T-cell regulator selected from the group comprising PD1, PD-L1, OX40, TIM-3, LAGS, CD137(4-1BB) and a non-codiung immuno-modulating DNA.

公开(公告)号：US10280424B2

公开(公告)日：2019-05-07

申请号：US14899601

申请日：2015-02-18

Applicant: Mologen AG

Inventor： Christiane Kleuss ,  Kerstin Kapp ,  Burghardt Wittig ,  Matthias Schroff

IPC: C12N15/117 ,  A61K39/39 ,  A61K48/00 ,  A61K39/00

Abstract: The present invention relates to a covalently closed DNA construct, a pharmaceutical composition and a vaccine and their use for the modulation of the immune system. It provides a DNA construct for immunomodulation comprising a specific DNA sequence.